# Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

> **NCT02874430** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 29 (actual)

## Conditions studied

- Breast Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Uterine Corpus Cancer
- Uterine Corpus Carcinosarcoma

## Interventions

- **DRUG:** Metformin Hydrochloride
- **DRUG:** Doxycycline

## Key facts

- **NCT ID:** NCT02874430
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-08
- **Primary completion:** 2020-12-11
- **Final completion:** 2020-12-11
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** study closed early due to slow accrual
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02874430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02874430, "Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02874430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*